Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3wdPbia
via IFTTT